इसराइल - हिब्रू - Ministry of Health

sanofi - aventis israel ltd - adenosine - תמיסה להזרקה - adenosine 6 mg / 2 ml - adenosine - adenosine - rapid conversion to a normal sinus rhythm of paroxymal supraventicular tachycardias including those associated with accessory bypass tracts (wolf parkinson-white syndrome).

इसराइल - हिब्रू - Ministry of Health

sanofi - aventis israel ltd - ofloxacin 2 mg/ml - solution for infusion - ofloxacin - infections of kidney, urinarty tract, genital organs, respiratory tract, chronic and recurrent ear, nose and throat, skin and soft tissues, bones and joints, bacterial enteritis, abdominal cavity, including pelvis minor and septicemia caused by ofloxacin sensitive microorganisms. prevention of infections in patients with a signifcant reduction of resistance to infections,

इसराइल - हिब्रू - Ministry of Health

sanofi - aventis israel ltd - levofloxacin as hemihydrate - תמיסה לאינפוזיה - levofloxacin as hemihydrate 5 mg/ml - levofloxacin - levofloxacin - in adults for whom intravenous therapy is considered to be appropriate, tavanic solution for infusion is indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: community- acquired pneumonia, complicated urinary tract infections including pyelonephritis, skin and soft tissue infections.

इसराइल - हिब्रू - Ministry of Health

comex ltd - water for injections 100 % - solvent for parenteral use - for use as a sterile solvent for the preparation of medicine intended for parenteral administration where water is a component of the preparation and for reconstituting or diluting medicines for parenteral administration immediatly after use.

इसराइल - हिब्रू - Ministry of Health

padagis israel agencies ltd, israel - ferrous sulfate - טבליה - ferrous sulfate 247.25 mg - iron bivalent, oral preparations - prevention and treatment of iron deficiency anemia.

इसराइल - हिब्रू - Ministry of Health

sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

इसराइल - हिब्रू - Ministry of Health

sanofi - aventis israel ltd - cromoglicic acid as sodium 2 %w/v - eye drops - cromoglicic acid - preventive treatment for all types of allergic conjunctivitis.

इसराइल - हिब्रू - Ministry of Health

sanofi - aventis israel ltd - enoxaparin sodium - תמיסה להזרקה - enoxaparin sodium 150 mg/ml - enoxaparin - enoxaparin - for treatment of deep vein thrombosis (dvt) once daily. treatment of pulmonary embolism once daily.

इसराइल - हिब्रू - Ministry of Health

sanofi - aventis israel ltd - ferrous gluconate as iron iii sodium ferric glugonate compl. 62.5 mg / 5 ml - solution for injection - various combinations - severe iron deficiency states only when oral administration has been found impossible in cases of gastrointestinal malabsorption which rules out oral iron therapy patients treated by dialysis getting erythropoietin.

इसराइल - हिब्रू - Ministry of Health

sanofi - aventis israel ltd - docetaxel as trihydrate 20 mg / 1 ml - concentrate for solution for infusion - docetaxel - breast cancer: taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.